Adjuvant Developed with NIH Funding Enhances Efficacy of India’s COVID-19 Vaccine
An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine.
Kansas-Based Company ViroVax Licenses Adjuvant to be Used in India’s First COVID-19 Vaccine in Human Trials
Kansas-based ViroVax LLC has licensed its adjuvant, Alhydroxiquim-II, to Bharat Biotech International Limited, an Indian biotech company.